Phase I-II trial of percutaneous intra-arterial cis-diamminedichloro platinum (II) for regionally confined malignancy

D. B. Calvo, Y. Z. Patt, S. Wallace, V. P. Chuang, R. S. Benjamin, J. D. Pritchard, Evan M Hersh, G. P. Bodey, G. M. Mavligit

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Forty-nine patients with regionally confined recurrent malignancy were treated with intra-arterial cis-diamminedichloro platinum II in a Phase I-II trial. A safe starting dose of 120 mg/m2 was established. An overall response rate of 45% was noted with significant responses observed among patients with melanoma, sarcoma, breast carcinoma, and neuroblastoma. Side effects included transient renal and bone marrow toxicity as well as neurotoxicity and ototoxicity (6%), the latter usually with residual damage. The rational basis and advantages of treatment with intra-arterial cis-platinum are discussed.

Original languageEnglish (US)
Pages (from-to)1278-1283
Number of pages6
JournalCancer
Volume45
Issue number6
StatePublished - 1980
Externally publishedYes

Fingerprint

Cisplatin
Neuroblastoma
Sarcoma
Melanoma
Neoplasms
Bone Marrow
Breast Neoplasms
Kidney
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Calvo, D. B., Patt, Y. Z., Wallace, S., Chuang, V. P., Benjamin, R. S., Pritchard, J. D., ... Mavligit, G. M. (1980). Phase I-II trial of percutaneous intra-arterial cis-diamminedichloro platinum (II) for regionally confined malignancy. Cancer, 45(6), 1278-1283.

Phase I-II trial of percutaneous intra-arterial cis-diamminedichloro platinum (II) for regionally confined malignancy. / Calvo, D. B.; Patt, Y. Z.; Wallace, S.; Chuang, V. P.; Benjamin, R. S.; Pritchard, J. D.; Hersh, Evan M; Bodey, G. P.; Mavligit, G. M.

In: Cancer, Vol. 45, No. 6, 1980, p. 1278-1283.

Research output: Contribution to journalArticle

Calvo, DB, Patt, YZ, Wallace, S, Chuang, VP, Benjamin, RS, Pritchard, JD, Hersh, EM, Bodey, GP & Mavligit, GM 1980, 'Phase I-II trial of percutaneous intra-arterial cis-diamminedichloro platinum (II) for regionally confined malignancy', Cancer, vol. 45, no. 6, pp. 1278-1283.
Calvo DB, Patt YZ, Wallace S, Chuang VP, Benjamin RS, Pritchard JD et al. Phase I-II trial of percutaneous intra-arterial cis-diamminedichloro platinum (II) for regionally confined malignancy. Cancer. 1980;45(6):1278-1283.
Calvo, D. B. ; Patt, Y. Z. ; Wallace, S. ; Chuang, V. P. ; Benjamin, R. S. ; Pritchard, J. D. ; Hersh, Evan M ; Bodey, G. P. ; Mavligit, G. M. / Phase I-II trial of percutaneous intra-arterial cis-diamminedichloro platinum (II) for regionally confined malignancy. In: Cancer. 1980 ; Vol. 45, No. 6. pp. 1278-1283.
@article{9916119e48c94552afb78f197145468f,
title = "Phase I-II trial of percutaneous intra-arterial cis-diamminedichloro platinum (II) for regionally confined malignancy",
abstract = "Forty-nine patients with regionally confined recurrent malignancy were treated with intra-arterial cis-diamminedichloro platinum II in a Phase I-II trial. A safe starting dose of 120 mg/m2 was established. An overall response rate of 45{\%} was noted with significant responses observed among patients with melanoma, sarcoma, breast carcinoma, and neuroblastoma. Side effects included transient renal and bone marrow toxicity as well as neurotoxicity and ototoxicity (6{\%}), the latter usually with residual damage. The rational basis and advantages of treatment with intra-arterial cis-platinum are discussed.",
author = "Calvo, {D. B.} and Patt, {Y. Z.} and S. Wallace and Chuang, {V. P.} and Benjamin, {R. S.} and Pritchard, {J. D.} and Hersh, {Evan M} and Bodey, {G. P.} and Mavligit, {G. M.}",
year = "1980",
language = "English (US)",
volume = "45",
pages = "1278--1283",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Phase I-II trial of percutaneous intra-arterial cis-diamminedichloro platinum (II) for regionally confined malignancy

AU - Calvo, D. B.

AU - Patt, Y. Z.

AU - Wallace, S.

AU - Chuang, V. P.

AU - Benjamin, R. S.

AU - Pritchard, J. D.

AU - Hersh, Evan M

AU - Bodey, G. P.

AU - Mavligit, G. M.

PY - 1980

Y1 - 1980

N2 - Forty-nine patients with regionally confined recurrent malignancy were treated with intra-arterial cis-diamminedichloro platinum II in a Phase I-II trial. A safe starting dose of 120 mg/m2 was established. An overall response rate of 45% was noted with significant responses observed among patients with melanoma, sarcoma, breast carcinoma, and neuroblastoma. Side effects included transient renal and bone marrow toxicity as well as neurotoxicity and ototoxicity (6%), the latter usually with residual damage. The rational basis and advantages of treatment with intra-arterial cis-platinum are discussed.

AB - Forty-nine patients with regionally confined recurrent malignancy were treated with intra-arterial cis-diamminedichloro platinum II in a Phase I-II trial. A safe starting dose of 120 mg/m2 was established. An overall response rate of 45% was noted with significant responses observed among patients with melanoma, sarcoma, breast carcinoma, and neuroblastoma. Side effects included transient renal and bone marrow toxicity as well as neurotoxicity and ototoxicity (6%), the latter usually with residual damage. The rational basis and advantages of treatment with intra-arterial cis-platinum are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0018905095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018905095&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 1278

EP - 1283

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -